Influenza A virus subtype H3N2 (also H3N2) is a subtype of viruses that cause influenza (flu). H3N2 viruses can infect birds and mammals. In birds, humans, and pigs, the virus has mutated into many strains. H3N2 is increasingly abundant in seasonal influenza, which kills an estimated 36,000 people in the United States each year.
Over 40,000 people die each year in the United States from influenza-related diseases. In patients whose immune systems are compromised, antiviral therapy may be life-saving, but it needs to be initiated quickly. It is therefore crucial to diagnose and type the influenza rapidly.
The over-the-counter anti-inflammatory drug naproxen may also exhibit antiviral activity against influenza A virus, according to a team of French scientists. The finding, the result of a structure-based investigation, is published online ahead of print in the journal Antimicrobial Agents and Chemotherapy.
This year's unusually long and rocky flu season would be nothing compared to the pandemic that could occur if bird flu became highly contagious among humans, which is why UCLA researchers and their colleagues are creating new ways to predict where an outbreak could emerge.
Dr. Martin Richter (pharmacology), investigator with the Centre de recherche clinique Étienne-Le Bel (CRCELB) at the Centre hospitalier universitaire de Sherbrooke (CHUS) and professor in the Faculty of Medicine and Health Sciences of the Université de Sherbrooke (UdeS), and his collaborators have identified a new function of the enzyme matriptase, present in the human respiratory system, that can activate a viral protein involved in infections caused by the H1N1 influenza (or flu) virus.
Deadly flu viruses, including the H5N1 bird flu and H3N2 swine flu, may have met their match in FluGen's universal vaccine, REDEE FLU.
Loyola Flu Central, a weekly snapshot of flu activity locally, regionally and nationally is now available on the Loyola University Health System web site, through Twitter and on Facebook.
The U.S. Food and Drug Administration today announced that it has approved Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology. Flublok is approved for the prevention of seasonal influenza in people 18 through 49 years of age.
Researchers report for the first time the seroprevalence of three strains of avian influenza viruses in pigs in southern China, but not the H5N1 avian influenza virus. Their research, published online ahead of print in the Journal of Clinical Microbiology, has implications for efforts to protect the public health from pandemics.
NanoViricides, Inc. reported today that its oral FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of the H3N2 influenza A virus.
The U.S. Food and Drug Administration announced today that it has approved the 2012-2013 influenza (flu) vaccine formulation for all six manufacturers licensed to produce and distribute the vaccines in the United States.
Inovio Pharmaceuticals, Inc. announced today that the first patients have been treated in a clinical trial evaluating immune responses in elderly adults immunized with Inovio's H1N1 SynCon universal influenza vaccine.
Not only does the type of flu virus affect a patient's outcome, but a new research report appearing in the Journal of Leukocyte Biology suggests that the number of viruses involved in the initial infection may be important too.
Inovio Pharmaceuticals, Inc. announced today that its SynCon avian influenza vaccine generated protective HAI titers against six different unmatched strains of H5N1 in a phase I clinical trial - a distinct clinical achievement on Inovio's path to develop universal influenza vaccines.
Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2012.
All Care Inala Medical Centre doctor Michael Ho said flu shots were becoming more popular each year. “Flu seasons tends to begin in late March early April to June,” he said. “More and more people are opting to get vaccinations because they are promoted well within the community.” He added, “It is particularly important for elderly people to be immunized because their immune system is already not at its best…This is also the case for people who have chronic medical conditions like diabetes, severe asthma, or heart disease. With their current condition, if they catch the flu they can end up with a worse outcome.”
NanoViricides, Inc. announced today that March 29th, 2012 has been confirmed by the US FDA as the date for its initial meeting with the Company's scientists. This pre-IND meeting will focus on FluCide, designated as NV-INF-1, the Company's novel anti-influenza drug.
MedImmune today announced that the U.S. Food and Drug Administration (FDA) has approved FluMist Quadrivalent (Influenza Vaccine Live, Intranasal) for prevention of influenza.
Dr. Joseph Bresee, chief of the epidemiology prevention branch at the influenza division at the Centers for Disease Control and Prevention (CDC), said for the third consecutive week this season the percent of respiratory specimen testing positive for flu surpassed 10 percent, which is generally a marker to indicate the flu season has begun. “This is the latest start to a flu season in the past 29 years,” said Dr. Bresee.
Researchers have found that on infecting 41 healthy volunteers with different strains of flu virus, those with higher levels of a specific type of white blood cell were less likely to develop severe illness. Now the team of researchers hopes to mimic the natural resistance shown by some of the volunteers, by creating a vaccine that boosts levels of a particular subset of the 'T-cells'.
According to World Health Organization researchers there is a rise in Australia in the number of seasonal influenza cases resistant to Tamiflu, the most commonly used antiviral drug. The rise in such cases involving the pandemic 2009 A (H1N1) flu strain, also known as swine flu, took place during Australia's most recent winter: May through August of 2011.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.